Fig. 3From: Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanismsTumor cell-intrinsic factors contributing to acquired resistance to ICI therapy. A: Neoantigens are in partial or total eliminated conferring poor immunogenicity and acquired resistance to ICIs therapy. B: β2M mutations affect the presentation of peptide MHC-I complexes to T cells, thus leading to the tumor cells not being recognized by T cells. C: Mutations of JAK1 and JAK2 make the tumor cells insensitive to IFN-γ secreted by T-cellsBack to article page